BioCentury
ARTICLE | Company News

Nicox, Re-Vana partner for sustained-release formulations for IOP

November 3, 2017 6:58 PM UTC

Nicox S.A. (Euronext:COX) and Re-Vana Therapeutics Ltd. (Belfast, U.K.) partnered to develop Re-Vana's EyeLief drug delivery platform for sustained release of Nicox's stand-alone nitric oxide (NO)-donors to reduce intraocular pressure (IOP).

Under the non-exclusive agreement, Re-Vana will develop EyeLief implants containing Nicox's NO-donors and oversee initial in vitro studies to evaluate the implants' sustained-release characteristics. The companies will jointly own co-developed IP regarding sustained-release formulations. Specific financial terms were not disclosed, but the companies said payments by Nicox related to the agreement were not considered material by Nicox...

BCIQ Company Profiles

Nicox S.A.